NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MRSN

Mersana Therapeutics Inc

Jun 30 • 04:00PM ET

0.2960

Dollar change +0.0050
Percentage change 1.72	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN ALNY EXEL SRPT NBIX SAVA BPMC AGIO IMMP

| Held by: VTI VXF VTWO IBB IWM CHNA IWO IWN VTWG IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.60	Insider Own	22.30%	Shs Outstand	124.63M	Perf Week	-13.09%
Market Cap	36.89M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	-0.30%	Shs Float	96.84M	Perf Month	-15.19%
Enterprise Value	-41.10M	PEG	-	EPS next Q	-0.16	Inst Own	50.18%	Short Float	15.56%	Perf Quarter	-22.00%
Income	-74.01M	P/S	1.08	EPS this Y	-6.99%	Inst Trans	-21.47%	Short Ratio	5.30	Perf Half Y	-81.73%
Sales	34.01M	P/B	-	EPS next Y	2.50%	ROA	-47.62%	Short Interest	15.07M	Perf YTD	-79.30%
Book/sh	-0.25	P/C	0.36	EPS next 5Y	-8.65%	ROE	-505.14%	52W High	2.83 -89.54%	Perf Year	-85.35%
Cash/sh	0.82	P/FCF	-	EPS past 3/5Y	38.35% 2.74%	ROIC	-	52W Low	0.26 14.33%	Perf 3Y	-93.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	880.21% -0.78%	Gross Margin	95.53%	Volatility	10.11% 9.45%	Perf 5Y	-98.61%
Dividend TTM	-	EV/Sales	-1.21	EPS Y/Y TTM	47.20%	Oper. Margin	-225.98%	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.83	Sales Y/Y TTM	-11.21%	Profit Margin	-217.64%	RSI (14)	37.61	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	1.83	EPS Q/Q	-21.89%	SMA20	-17.26%	Beta	0.78	Target Price	4.50
Payout	-	Debt/Eq	-	Sales Q/Q	-70.21%	SMA50	-17.85%	Rel Volume	1.25	Prev Close	0.29
Employees	102	LT Debt/Eq	-	Earnings	May 15 BMO	SMA200	-72.92%	Avg Volume	2.84M	Price	0.30
IPO	Jun 28, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.35% -54.47%	Trades		Volume	3,557,389	Change	1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-25	Initiated	William Blair	Outperform
Nov-15-24	Resumed	Citigroup	Buy	$5
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral	$5
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform	$2 → $7
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy	$7
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy	$6
Dec-04-23	Upgrade	Citigroup	Neutral → Buy	$1 → $5
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$7 → $1
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral	$11 → $5
Jun-15-23	Initiated	Guggenheim	Buy	$14
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight	$10
Jan-20-23	Initiated	Citigroup	Buy	$12
Nov-21-22	Initiated	Truist	Buy	$12
Oct-15-21	Resumed	BTIG Research	Buy	$32

Show Previous Ratings

Jun-02-25 08:10AM	Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting (GlobeNewswire) +8.79%
May-20-25 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-16-25 03:06AM	Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +8.14%
12:19AM	Q1 2025 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 09:20AM	CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results (GlobeNewswire) -17.24%
08:15AM	Loading…
08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results (GlobeNewswire)
May-14-25 09:59AM	Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +6.09%
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-13-25 05:45PM	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 07:00AM	Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer (GlobeNewswire) -13.21%
06:19AM	Bluebird pleads for deal support; Unity, Mersana lay off staff (BioPharma Dive)
Apr-23-25 10:12AM	Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting (GlobeNewswire)
Apr-04-25 04:05PM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 08:01AM	Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress (GlobeNewswire)
02:00AM	Loading…
Mar-04-25 02:00AM	Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +5.90%
Mar-03-25 11:09PM	Q4 2024 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -8.29%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-28-25 07:17AM	What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings (GuruFocus.com)
Feb-25-25 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.21%
Feb-24-25 04:01PM	Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 (GlobeNewswire)
Feb-07-25 04:05PM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.68% -6.67%
Jan-30-25 08:00AM	Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) +8.47%
Jan-10-25 12:49PM	Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? (Benzinga) -44.62%
06:02AM	Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) (GlobeNewswire)
06:00AM	Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer (GlobeNewswire)
Nov-14-24 02:06AM	Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
01:32AM	Q3 2024 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-24 08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +19.55%
07:00AM	Loading…
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 (GlobeNewswire) +16.42%
Oct-15-24 11:01AM	SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc (GuruFocus.com)
Aug-13-24 08:20AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 08:00AM	Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024 (GlobeNewswire)
May-22-24 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 04:36PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.94%
03:15PM	Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
May-09-24 11:55AM	MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -27.50%
08:05AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:59AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-03-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 (GlobeNewswire)
Apr-04-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 08:41AM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.16%
Feb-28-24 09:49PM	Q4 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.58%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:35AM	Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 08:01AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.17%
Feb-21-24 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 (GlobeNewswire)
Feb-20-24 10:00AM	Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-01-24 08:00AM	Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +6.96%
Jan-05-24 08:01AM	Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-23 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15% +7.37%
Nov-08-23 02:42PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:13AM	Q3 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:10AM	Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 04:30PM	Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023 (GlobeNewswire) +7.21%
08:00AM	Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056 (GlobeNewswire)
Sep-07-23 06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-06-23 07:00AM	Mersana Therapeutics Announces Changes in Leadership (GlobeNewswire) +7.89%
Aug-18-23 09:35AM	After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN) (Zacks)
Aug-16-23 09:35AM	Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround (Zacks) -6.35%
Aug-08-23 09:40AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Mersana Therapeutics Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.24%
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +17.76%
03:14AM	4 big analyst cuts: Snap slashed to Hold, Southwest gets several downgrades (Investing.com)
Jul-27-23 09:34PM	EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc (GuruFocus.com) -72.63%
01:44PM	Mersana slashes half its staff, loses $400M in value after trial failure (American City Business Journals)
07:06AM	Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization (GlobeNewswire)
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jul-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-16-23 10:43AM	Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold (Zacks) -10.80%
02:26AM	5 big analyst cuts: SoFi Technologies slashed with 3 downgrades, shares plunge (Investing.com)
Jun-15-23 09:32AM	Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser (Motley Fool) -59.27%
07:36AM	US FDA puts Mersana Therapeutics's ovarian cancer study on hold (Reuters)
07:30AM	Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials (GlobeNewswire)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +5.45%
Jun-02-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.82%
May-28-23 09:06AM	Those who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127% (Simply Wall St.)
May-24-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-23 08:35AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.82%
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.00%
May-03-23 08:00AM	Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire) +46.12%
May-02-23 08:00AM	Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023 (GlobeNewswire) -7.01%
Apr-26-23 04:05PM	Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 11:07AM	Getting In Cheap On Mersana Therapeutics, Inc. (NASDAQ:MRSN) Is Unlikely (Simply Wall St.) +5.54%
Apr-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-05-23 02:00PM	J.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential (TipRanks)
Mar-16-23 11:20AM	Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More (Zacks) +6.37%
Mar-13-23 02:00PM	FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death (Benzinga)
07:54AM	UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death (Reuters)
07:30AM	Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial (GlobeNewswire)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '25	Option Exercise	0.00	8,685	0	61,073	Jan 17 07:27 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 16 '25	Sale	0.58	3,554	2,061	57,519	Jan 17 07:27 PM
Protopapas Anna	Director	Jan 15 '25	Option Exercise	0.00	21,250	0	176,678	Jan 17 07:26 PM
Protopapas Anna	Director	Jan 16 '25	Sale	0.58	8,637	5,009	168,041	Jan 17 07:26 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '25	Option Exercise	0.00	19,791	0	265,721	Jan 17 07:25 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 16 '25	Sale	0.58	8,048	4,668	257,673	Jan 17 07:25 PM
Huber Martin H. Jr.	President, CEO	Jan 15 '25	Option Exercise	0.00	11,062	0	127,389	Jan 17 07:21 PM
Huber Martin H. Jr.	President, CEO	Jan 16 '25	Sale	0.58	4,514	2,618	122,875	Jan 17 07:21 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '25	Option Exercise	0.00	20,833	0	129,863	Jan 17 07:20 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 16 '25	Sale	0.58	8,470	4,913	121,393	Jan 17 07:20 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 15 '25	Option Exercise	0.00	12,500	0	83,392	Jan 17 07:18 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 16 '25	Sale	0.58	5,096	2,956	78,296	Jan 17 07:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 15 '25	Option Exercise	0.00	14,583	0	74,811	Jan 17 07:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 16 '25	Sale	0.58	5,939	3,445	68,872	Jan 17 07:18 PM
Timothy B. Lowinger	Officer	Jan 16 '25	Proposed Sale	0.61	8,048	4,909		Jan 17 07:05 PM
Brian DeSchuytner	Officer	Jan 16 '25	Proposed Sale	0.61	8,470	5,167		Jan 17 07:05 PM
Alejandra Carvajal	Officer	Jan 16 '25	Proposed Sale	0.61	5,096	3,109		Jan 17 07:05 PM
Mohan Bala	Officer	Jan 16 '25	Proposed Sale	0.61	5,939	3,623		Jan 17 07:04 PM
Anna Protopapas	Director	Jan 16 '25	Proposed Sale	0.61	8,637	5,269		Jan 17 07:04 PM
Mohan Bala	Officer	Jan 14 '25	Proposed Sale	0.63	3,253	2,049		Jan 17 07:02 PM
Protopapas Anna	Director	Jan 14 '25	Option Exercise	0.00	16,750	0	161,619	Jan 16 05:25 PM
Protopapas Anna	Director	Jan 15 '25	Sale	0.63	6,191	3,900	155,428	Jan 16 05:25 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '25	Option Exercise	0.00	4,783	0	54,179	Jan 16 05:25 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '25	Sale	0.63	1,791	1,128	52,388	Jan 16 05:25 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '25	Option Exercise	0.00	4,792	0	247,724	Jan 16 05:24 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '25	Sale	0.63	1,794	1,130	245,930	Jan 16 05:24 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '25	Option Exercise	0.00	6,250	0	111,361	Jan 16 05:23 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '25	Sale	0.63	2,331	1,469	109,030	Jan 16 05:23 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '25	Option Exercise	0.00	2,500	0	71,844	Jan 16 05:23 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 15 '25	Sale	0.63	952	600	70,892	Jan 16 05:23 PM
Protopapas Anna	Director	Jan 15 '25	Proposed Sale	0.64	6,191	3,962		Jan 16 05:21 PM
Lowinger Timothy B	Officer	Jan 15 '25	Proposed Sale	0.64	1,794	1,148		Jan 16 05:20 PM
DeSchuytner Brian	Officer	Jan 15 '25	Proposed Sale	0.64	2,331	1,492		Jan 16 05:19 PM
Protopapas Anna	Director	Jan 13 '25	Option Exercise	0.00	31,250	0	156,403	Jan 15 09:20 PM
Protopapas Anna	Director	Jan 14 '25	Sale	0.66	11,534	7,612	144,869	Jan 15 09:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 13 '25	Option Exercise	0.00	2,646	0	50,403	Jan 15 09:19 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '25	Sale	0.66	1,007	665	49,396	Jan 15 09:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 13 '25	Option Exercise	0.00	9,375	0	246,415	Jan 15 09:18 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '25	Sale	0.66	3,483	2,299	242,932	Jan 15 09:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 13 '25	Option Exercise	0.00	10,000	0	108,824	Jan 15 09:17 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '25	Sale	0.66	3,713	2,451	105,111	Jan 15 09:17 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 13 '25	Option Exercise	0.00	8,958	0	72,674	Jan 15 09:17 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '25	Sale	0.66	3,330	2,198	69,344	Jan 15 09:17 PM
Bala Mohan	SVP, Chief Development Officer	Jan 13 '25	Option Exercise	0.00	8,750	0	63,481	Jan 15 09:16 PM
Bala Mohan	SVP, Chief Development Officer	Jan 14 '25	Sale	0.66	3,253	2,147	60,228	Jan 15 09:16 PM
Protopapas Anna	Director	Jan 14 '25	Proposed Sale	0.63	11,534	7,266		Jan 15 09:15 PM
Bala Mohan	SVP, Chief Development Officer	Oct 25 '24	Option Exercise	0.00	6,250	0	56,615	Oct 29 04:43 PM
Bala Mohan	SVP, Chief Development Officer	Oct 28 '24	Sale	1.90	1,884	3,580	54,731	Oct 29 04:43 PM
Bala, Mohan	Officer	Oct 28 '24	Proposed Sale	2.04	1,884	3,843		Oct 29 04:26 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 01 '24	Option Exercise	0.00	50,000	0	108,511	Oct 07 05:48 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 02 '24	Sale	2.00	8,089	16,178	100,422	Oct 07 05:48 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 03 '24	Sale	1.96	5,598	10,972	94,824	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	77,403	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 02 '24	Sale	2.00	8,089	16,178	69,314	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 03 '24	Sale	1.96	5,598	10,972	63,716	Oct 07 05:48 PM
Bala Mohan	SVP, Chief Development Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	64,052	Oct 07 05:47 PM
Bala Mohan	SVP, Chief Development Officer	Oct 02 '24	Sale	2.00	8,089	16,178	55,963	Oct 07 05:47 PM
Bala Mohan	SVP, Chief Development Officer	Oct 03 '24	Sale	1.96	5,598	10,972	50,365	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 01 '24	Option Exercise	0.00	30,000	0	55,973	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 02 '24	Sale	2.00	4,855	9,710	51,118	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 03 '24	Sale	1.96	3,361	6,588	47,757	Oct 07 05:47 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	249,329	Oct 07 05:46 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 02 '24	Sale	2.00	8,089	16,178	241,240	Oct 07 05:46 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 03 '24	Sale	1.96	5,598	10,972	235,642	Oct 07 05:46 PM
Bala, Mohan	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:20 PM
Carvajal, Alejandra	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:19 PM
Brian DeSchuytner	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:18 PM
Timothy B. Lowinger	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:18 PM
Huber Martin H. Jr.	President, CEO	Sep 11 '24	Option Exercise	0.00	166,750	0	166,750	Sep 13 05:08 PM
Huber Martin H. Jr.	President, CEO	Sep 12 '24	Sale	1.76	50,423	88,744	116,327	Sep 13 05:08 PM
Huber, Martin H. Jr.	Officer, Director	Sep 12 '24	Proposed Sale	1.77	50,423	89,249		Sep 13 05:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRSN

Mersana Therapeutics Inc

Upgrade your FINVIZ experience